→ Matrix Capital Management has scooped up $42 million worth of Adaptimmune stock $ADAP, paying a slight premium for the block of shares. “We are delighted to welcome Matrix to our shareholder base through a purchase of 7 million ADSs, which raises a further $42 million to add to the $62 million raised in our public offering, which closed last week,” says CEO James Noble.
→ Australia’s Novogen $NVGN is dropping a preclinical therapy after concluding that it didn’t have much of a future. It’s now cutting its headcount by an unspecified number and focusing on its clinical efforts.
→ KaloBios CEO Cameron Durrant says the company is still on track with its development plans for benznidazole for Chagas disease. The biotech $KBIO plans to file its IND in May and, with the FDA’s approval, use existing data to help with an NDA filing in early 2018.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription